Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 22, 2013, Pages

  Weiskopf, Daniela ^a   Angelo, Michael A ^a   De Azeredo, Elzinandes L ^a   Sidney, John ^a   Greenbaum, Jason A ^a   Fernando, Anira N ^b   Broadwater, Anne ^c   Kolla, Ravi V ^a   De Silva, Aruna D ^a,b   De Silva, Aravinda M ^c   Mattia, Kimberly A ^d   Doranz, Benjamin J ^d   Grey, Howard M ^a   Shresta, Sujan ^a   Peters, Bjoern ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Genetech Research Institute   (Sri Lanka)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Integral Molecular Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN;

ADULT; ALLELE; ANTIGENICITY; ARTICLE; BLOOD DONOR; CD8+ T LYMPHOCYTE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY INFECTION; PRIORITY JOURNAL; SECONDARY INFECTION; SEROTYPE;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VIRUS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC MEMORY; MONOCYTES; POLYPROTEINS; SEROEPIDEMIOLOGIC STUDIES; SRI LANKA;

DENGUE VIRUS;

EID: 84878446213     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305227110     Document Type: Article

References (49)

1. Fu J, Tan BH, Yap EH, Chan YC, Tan YH (1992) Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90). Virology 188(2):953-958.
2. Suaya JA, et al. (2009) Cost of dengue cases in eight countries in the Americas and Asia: A prospective study. Am J Trop Med Hyg 80(5):846-855.
3. Guzman MG, et al. (2010) Dengue: A continuing global threat. Nat Rev Microbiol 8(12, Suppl):S7-S16.
4. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62:71-92.
5. Guzman A, Istúriz RE (2010) Update on the global spread of dengue. Int J Antimicrob Agents 36(Suppl 1):S40-S42.
6. Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38(1):172-180.
7. Sangkawibha N, et al. (1984) Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120(5):653-669.
8. Halstead SB (1988) Pathogenesis of dengue: Challenges to molecular biology. Science 239(4839):476-481.
9. Heinz FX, Stiasny K (2012) Flaviviruses and flavivirus vaccines. Vaccine 30(29): 4301-4306.
10. Morens DM (1994) Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 19(3):500-512.
11. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM (2010) Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis 10(10):712-722.
12. Zellweger RM, Prestwood TR, Shresta S (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7(2):128-139.
13. Balsitis SJ, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6(2):e1000790.
14. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140(4):527-533.
15. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibodymediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104(22):9422-9427.
16. Halstead SB, Rojanasuphot S, Sangkawibha N (1983) Original antigenic sin in dengue. Am J Trop Med Hyg 32(1):154-156.
17. Mongkolsapaya J, et al. (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9(7):921-927.
18. Davenport FM, Hennessy AV, Francis T, Jr. (1953) Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 98(6):641-656.
19. Klenerman P, Zinkernagel RM (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394(6692):482-485.
20. Malavige GN, et al. (2011) HLA class I and class II associations in dengue viral infections in a Sri Lankan population. PLoS ONE 6(6):e20581.
21. Stephens HA, et al. (2002) HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60(4):309-318.
22. Loke H, et al. (2001) Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: A double-edged sword? J Infect Dis 184(11):1369-1373.
23. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD (2010) Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS ONE 5(9).
24. Nguyen TP, et al. (2008) Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2(10):e304.
25. Falcón-Lezama JA, et al. (2009) HLA class I and II polymorphisms in Mexican Mestizo patients with dengue fever. Acta Trop 112(2):193-197.
26. Sierra B, et al. (2007) HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: Advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol 68(6):531-540.
27. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: A revised and updated classification. BMC Immunol 9:1.
28. Kanakaratne N, et al. (2009) Severe dengue epidemics in Sri Lanka, 2003-2006. Emerg Infect Dis 15(2):192-199.
29. Messer WB, et al. (2002) Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg 66(6): 765-773.
30. Tissera HA, et al. (2011) New dengue virus type 1 genotype in Colombo, Sri Lanka. Emerg Infect Dis 17(11):2053-2055.
31. Yauch LE, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182(8):4865-4873.
32. Zompi S, Santich BH, Beatty PR, Harris E (2012) Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 188(1):404-416.
33. Duangchinda T, et al. (2010) Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107(39):16922-16927.
34. Rothman AL (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11(8):532-543.
35. Zanotto PM, Gould EA, Gao GF, Harvey PH, Holmes EC (1996) Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci USA 93(2):548-553.
36. Rivino L, et al. (2013) Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 87(5):2693-2706.
37. Dung NT, et al. (2010) Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol 184(12):7281-7287.
38. Almeida JR, et al. (2009) Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113(25):6351-6360.
39. Park SH, et al. (2012) Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 143(4): 1048-1060.
40. Sabchareon A, et al. (2012) Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380(9853):1559-1567.
41. Guy B, et al. (2011) From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29(42): 7229-7241.
42. Nguyen TH, et al. (2004) Dengue hemorrhagic fever in infants: A study of clinical and cytokine profiles. J Infect Dis 189(2):221-232.
43. Monteiro SP, et al. (2012) HLA-A*01 allele: A risk factor for dengue haemorrhagic fever in Brazil's population. Mem Inst Oswaldo Cruz 107(2):224-230.
44. Hatch S, et al. (2011) Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203(9):1282-1291.
45. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50(3-4):201-212.
46. Kim Y, et al. (2012) Immune epitope database analysis resource. Nucleic Acids Res 40 (Web Server issue):W525-30.
47. Tissera HA, et al. (2010) Dengue Surveillance in Colombo, Sri Lanka: Baseline seroprevalence among children. Procedia in Vaccinology 2:109-112.
48. Kraus AA, MesserW, Haymore LB, de Silva AM(2007) Comparison of plaque-And flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45(11):3777-3780.
49. Weiskopf D, et al. (2011) Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 187(8):4268-4279.